Abstract
In recent years, there is a growing interest in research to investigate the importance of gut microbiome in health and diseases. This opens a new area of research for the role of microbial flora of the human gut in inflammation, energy homeostasis, pathogenesis of obesity and other associated disorders. Recent studies propose association of the gut microbiome with development of obesity and metabolic syndromes, such as type 2 diabetes mellitus (T2DM). The T2DM is a metabolic disease that is mainly caused by obesity-linked insulin resistance. The vascular effects of obesity appears to play a role in the development of Alzheimer’s disease (AD) that is one of the rapidly growing diseases of a late stage of life all over the world. Studies from both humans and mice models have been demonstrated the engagement of gut microbial flora in the pathogenesis of obesity and host metabolism. The aim of this review is to discuss the current findings that may explain the cascade of gut microbial flora participation in the development of obesity, T2DM and further initiation of AD. In addition, the available data regarding the mechanisms that have been proposed to elucidate the role of gut microbiota in weight gain and possible cause of T2DM and AD have been examined.
Keywords: Gut microbiota, obesity, metabolic disease, type 2 diabetes mellitus, Alzheimer’s disease.
CNS & Neurological Disorders - Drug Targets
Title:Role of Gut Microbiota in Obesity, Type 2 Diabetes and Alzheimer’s Disease
Volume: 13 Issue: 2
Author(s): Muhammad I. Naseer, Fehmida Bibi, Mohammed H. Alqahtani, Adeel G. Chaudhary, Esam I. Azhar, Mohammad A. Kamal and Muhammad Yasir
Affiliation:
Keywords: Gut microbiota, obesity, metabolic disease, type 2 diabetes mellitus, Alzheimer’s disease.
Abstract: In recent years, there is a growing interest in research to investigate the importance of gut microbiome in health and diseases. This opens a new area of research for the role of microbial flora of the human gut in inflammation, energy homeostasis, pathogenesis of obesity and other associated disorders. Recent studies propose association of the gut microbiome with development of obesity and metabolic syndromes, such as type 2 diabetes mellitus (T2DM). The T2DM is a metabolic disease that is mainly caused by obesity-linked insulin resistance. The vascular effects of obesity appears to play a role in the development of Alzheimer’s disease (AD) that is one of the rapidly growing diseases of a late stage of life all over the world. Studies from both humans and mice models have been demonstrated the engagement of gut microbial flora in the pathogenesis of obesity and host metabolism. The aim of this review is to discuss the current findings that may explain the cascade of gut microbial flora participation in the development of obesity, T2DM and further initiation of AD. In addition, the available data regarding the mechanisms that have been proposed to elucidate the role of gut microbiota in weight gain and possible cause of T2DM and AD have been examined.
Export Options
About this article
Cite this article as:
Naseer I. Muhammad, Bibi Fehmida, Alqahtani H. Mohammed, Chaudhary G. Adeel, Azhar I. Esam, Kamal A. Mohammad and Yasir Muhammad, Role of Gut Microbiota in Obesity, Type 2 Diabetes and Alzheimer’s Disease, CNS & Neurological Disorders - Drug Targets 2014; 13(2) . https://dx.doi.org/10.2174/18715273113126660147
DOI https://dx.doi.org/10.2174/18715273113126660147 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
The Role of Autophagy in Rheumatic Disease
Current Drug Targets OX40:OX40L Axis: Emerging Targets for Immunotherapy of Human Disease
Current Immunology Reviews (Discontinued) T-Cell Antigen Receptor Assembly and Cell Surface Expression Is Not Affected by Treatment with T-Cell Antigen Receptor-Alpha Chain Transmembrane Peptide
Protein & Peptide Letters Fluorescent Substrates Useful as High Throughput Screening Tools for ADAM9
Combinatorial Chemistry & High Throughput Screening Gene Therapy and Targeted Toxins for Glioma
Current Gene Therapy Role of Adenosine Receptors in Rare Neurodegenerative Diseases with Motor Symptoms
Current Protein & Peptide Science Subject Index to Volume 10
Current Medicinal Chemistry Therapeutic Targeting of Epigenetic Components in Amyotrophic Lateral Sclerosis (ALS)
Current Medicinal Chemistry Immunomodulation of the Allergic Inflammatory Response: New Developments
Inflammation & Allergy - Drug Targets (Discontinued) Lecithin (Phosphatidylcholine): Healthy Dietary Supplement or Dangerous Toxin?
The Natural Products Journal Matrine: Bioactivities and Structural Modifications
Current Topics in Medicinal Chemistry Vitamin D and the Adaptive Immune System with Special Emphasis to Allergic Reactions and Allograft Rejection
Inflammation & Allergy - Drug Targets (Discontinued) Orchestrating HIV Neutralization by Secondary Immune Response- Mediated Induction of RF Antibodies
Current Immunology Reviews (Discontinued) Targeting ADAM12 in Human Disease: Head, Body or Tail?
Current Pharmaceutical Design Virulence Mechanisms Displayed by Salmonella to Impair Dendritic Cell Function
Current Medicinal Chemistry Therapeutic Benefits of Regulating Inflammation in Autoimmunity
Inflammation & Allergy - Drug Targets (Discontinued) The Pathophysiology of Heme in the Brain
Current Alzheimer Research Cognitive Dysfunction in Depression – Pathophysiology and Novel Targets
CNS & Neurological Disorders - Drug Targets Recent Patents in Toll-like Receptor Pathways and Relevance to Cancer
Recent Patents on Anti-Cancer Drug Discovery The Heme Oxygenase System and Type-1 Diabetes
Current Pharmaceutical Design